Getinge Group: Shareholders Representing 70% of Outstanding Shares in Pulsion Have Agreed to Accept Getinge's Offer in Intended

  Getinge Group: Shareholders Representing 70% of Outstanding Shares in
  Pulsion Have Agreed to Accept Getinge's Offer in Intended Acquisition of
  Pulsion Medical Systems

Business Wire

GETINGE, Sweden -- December 5, 2013

Regulatory News:

As announced yesterday, Getinge (STO:GETIB) has decided to issue a public
tender offer to acquire all shares in Pulsion Medical Systems SE (“Pulsion”),
listed on the German Stock Exchange (Deutsche Börse). Getinge plans to offer
the shareholders in Pulsion to tender their shares for an offer price of 16.90
€ per share in cash. The offer will be made by a fully-owned German Getinge
subsidiary in accordance with the German Securities and Takeover Act. The
offer will be subject to the terms and conditions to be set forth in the offer
document.

A shareholder pool led by Forum European Smallcaps GmbH and a number of other
shareholders, who together represent approximately 70% of all issued shares
and voting rights in Pulsion, have irrevocably undertaken to accept the offer
from Getinge.

Dr. Wittek, Chairman of Pulsion’s Board of Directors, has stated that Pulsion
considers the offer to be a great opportunity to combine its leading position
in hemodynamic monitoring in Europe with the global sales and marketing power
of Getinge. After review of the offer document, the Board of Directors of
Pulsion will provide a final recommendation to the shareholders.

To read the press announcement from yesterday please visit
www.getingegroup.com where, as soon as completed, the offer document also will
be published.

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and
life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care. The information is such that Getinge AB must
disclose in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act.

This information was brought to you by Cision http://news.cision.com

Contact:

Getinge Group
Ulf Grunander, CFO,
+46 10335 55 80
ulf.grunander@getinge.com
 
Press spacebar to pause and continue. Press esc to stop.